Nephron-Sparing Management of Low Grade UTUC with UGN-101 for Instillation-The OLYMPUS Trial

E. David Crawford, MD, and Brian R. Hu, MD, discuss the results of the use of UGN-101 to treat upper-tract urothelial cancer in the OLYMPUS trial, where it was shown to ablate low-grade tumors with a high initial complete response rate. They delve into the unique properties of UGN-101 and its successes and demonstrated side effects from the trial, as well as an upcoming study investigating a different formulation of the drug for treating bladder cancer.

Read More